Federated Hermes
LENZ

Federated Hermes’s LENZ Therapeutics LENZ Stock Holding History

Federated Hermes’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-62,636
Closed -$1M – 2181
2025
Q4 		$1M Buy
+62,636
New +$1.83M ﹤0.01% 1123
2025
Q1 		– Sell
-45
Closed -$1.3K – 2213
2024
Q4 		$1.3K Buy
+45
New +$1.37K ﹤0.01% 2005
2023
Q3 		– Sell
-58,308
Closed -$1.06M – 2215
2023
Q2 		$1.06M Sell
58,308
-258
-0.4% -$5.16K ﹤0.01% 1122
2023
Q1 		$1M Sell
58,566
-92,648
-61% -$1.5M ﹤0.01% 1166
2022
Q4 		$3.51M Buy
151,214
+74
+0% +$1.72K 0.01% 758
2022
Q3 		$3.35M Buy
151,140
+239
+0.2% +$5.7K 0.01% 763
2022
Q2 		$2.9M Hold
150,901
– – 0.01% 830
2022
Q1 		$5.39M Hold
150,901
– – 0.01% 763
2021
Q4 		$13.1M Hold
150,901
– – 0.02% 583
2021
Q3 		$17.3M Buy
150,901
+58,044
+63% +$8.6M 0.03% 511
2021
Q2 		$20M Buy
+92,857
New +$16.2M 0.04% 482

Other funds holding LENZ

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
7IH
72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return

Federated Hermes's LENZ Position: Q1 2026 in Review

Federated Hermes sold out of LENZ Therapeutics (LENZ) in Q1 2026, closing a stake of 62,636 shares — an estimated $1M sold.

Federated Hermes first reported a position in LENZ in Q2 2021 and held it in 11 quarters. The position peaked at $20M in Q2 2021. 145 funds tracked by Wall St. Rank hold LENZ as of Q1 2026.

  • Federated Hermes reported no remaining LENZ Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Federated Hermes sold 62,636 LENZ Therapeutics shares in Q1 2026, an estimated $1M.
  • Federated Hermes first reported a position in LENZ Therapeutics in Q2 2021 and held it in 11 quarters.
  • Federated Hermes's LENZ Therapeutics position peaked at $20M in Q2 2021.
  • 145 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q1 2026.

Based on Federated Hermes's 13F filing for Q1 2026, filed 11 May 2026.